Peter Lindgren

Publications
Grants
CV
Public outreach and news

Articles

Article: BLOOD PRESSURE. 2025;34(1):2487583
Cost-effectiveness analysis of radiofrequency renal denervation for uncontrolled hypertension in Sweden
Kahan T; Johansen ML; Ryschon AM; Cao KN; Kolovetsios MD; Lindgren P; Pietzsch JB
Journal article: ESMO OPEN. 2025;10:105009
437P Benchmarking breast cancer survival: A case-mix model for fair hospital comparisons of 5 and 10-year breast cancer-specific mortality
Thurell J; Petrov I; Lindgren P; Bergh J; Fredriksson I; Kiani N; Hedayati E
Article: PHARMACOECONOMICS - OPEN. 2025;9(2):161-178
Incorporating Resource Constraints in Health Economic Evaluations: Overview and Methodological Considerations
Thokala P; Duarte H; Wright S; Husereau D; Durand-Zaleski I; Lindgren P; Postema R; Machnicki G; Garrison L
Article: JOURNAL OF MEDICAL ECONOMICS. 2024;27(1):1146-1156
Societal costs and quality of life associated with arginase 1 deficiency in a European setting - a multinational, cross-sectional survey
Olofsson S; Lofvendahl S; Widen J; Rudebeck M; Lindgren P; Stepien KM; Arnoux J-B; Pico MLC; Teles EL; Jacobson L
Journal article: VALUE IN HEALTH. 2024;27(12):s276
HPR6 Early Access Programs in Northwest European Countries
Birch C; Brådvik G; Larsen E; Lindgren P; Ehlers L
Article: JIMD REPORTS. 2024;65(6):450-460
Disease burden among patients with Arginase 1 deficiency and their caregivers: A multinational, cross-sectional survey
Olofsson S; Lofvendahl S; Widen J; Jacobson L; Lindgren P; Stepien KM; Arnoux J-B; Pico MLC; Teles EL; Rudebeck M
Journal article: VALUE IN HEALTH. 2023;26(12):s196-s197
EE738 Cost-Effectiveness of Renal Denervation for Uncontrolled Hypertension: An Analysis for Sweden Based on the SPYRAL HTN-ON MED Trial and Other Contemporary Evidence
Kahan T; Johansen ML; Ryschon AM; Cao K; Kolovetsios M; Lindgren P; Pietzsch J
Article: VALUE IN HEALTH REGIONAL ISSUES. 2023;37:81-87
The Disease Burden and Economic Burden of Cancer in 9 Countries in the Middle East and Africa
Hofmarcher T; Garcia AM; Wilking N; Lindgren P
Article: FRONTIERS IN NEUROLOGY. 2023;14:1175922
Precision medicine in neurodegeneration: the IHI-PROMINENT project
Tate A; Suarez-Calvet M; Ekelund M; Eriksson S; Eriksdotter MM; Van der Flier W; Georges J; Kivipelto MG; Kramberger M; Lindgren P; Lopez JDG; Lotjonen J; Persson S; Pla S; Solomon A; Thurfjell L; Wimo A; Winblad B; Jonsson L
Article: NATURE REVIEWS UROLOGY. 2023;20(8):494-501
Unanswered questions in prostate cancer - findings of an international multi-stakeholder consensus by the PIONEER consortium.
Omar MI; MacLennan S; Ribal MJ; Roobol MJ; Dimitropoulos K; van den Broeck T; MacLennan SJ; Axelsson SE; Gandaglia G; Willemse P-P; Mastris K; Ransohoff JB; Devecseri Z; Abbott T; De Meulder B; Bjartell A; Asiimwe A; N'Dow J; PIONEER Consortium
Journal article: TOBACCO PREVENTION AND CESSATION. 2023;9(Supplement)
Motivation 2 Quit (M2Q): Tobacco Cessation on Prescription – an effective treatment?
Tomson T; Leppänen A; Lindgren P; Sundberg CJ; Petzold M
Article: BLOOD PRESSURE MONITORING. 2023;28(2):86-95
Real-world long-term effects on blood pressure and other cardiovascular risk factors for patients in digital therapeutics
Willis M; Darwiche G; Carlsson M; Nilsson A; Wohlin J; Lindgren P
Article: VALUE IN HEALTH. 2023;26(4):3-10
Across-Country Variations of Real-World Data and Evidence for Drugs: A 5-European-Country Study
de Pouvourville G; Cunningham D; Fricke F-U; Lindgren P; Mantovani L; Murphy LA; Sola-Morales O; Mestre-Ferrandiz J; Akehurst R
Article: VALUE IN HEALTH. 2023;26(3):328-335
The Allocation of the Economic Value of Second-Generation Antipsychotics Over the Product Life Cycle: The Case of Risperidone in Sweden and the United Kingdom.
Berdud M; Wallin-Bernhardsson N; Zamora B; Lindgren P; Towse A
Article: FRONTIERS IN MEDICINE. 2023;10:1119506
A global analysis of the value of precision medicine in oncology - The case of non-small cell lung cancer
Hofmarcher T; Malmberg C; Lindgren P
Journal article: VALUE IN HEALTH. 2022;25(12):s156
EE510 A Global Analysis of the Value of Precision Medicine in Oncology – The Case of Non-Small Cell Lung Cancer
Hofmarcher T; Malmberg C; Lindgren P
Journal article: VALUE IN HEALTH. 2022;25(12):s91-s92
EE198 Integrating Health Economic Analysis into External Quality Assessment of Laboratory Tests: Evaluating Costs and Consequences of Bias in Lipid Tests in the Prevention of Cardiovascular Disease in Swedish Diabetes Patients
Keel G; Karlsson M; Tähti S; Galkus L; Örneholm F; Lindgren P
Article: JOURNAL OF CANCER POLICY. 2022;34:100362
Systemic anti-cancer therapy patterns in advanced non-small cell lung cancer in Europe
Hofmarcher T; Lindgren P; Wilking N
Article: PLOS ONE. 2022;17(12):e0278369
Motivation 2 Quit (M2Q): A cluster randomized controlled trial evaluating the effectiveness of Tobacco Cessation on Prescription in Swedish primary healthcare
Leppanen A; Lindgren P; Sundberg CJ; Petzold M; Tomson T
Article: PHARMACOECONOMICS. 2022;40(11):1095-1105
A Proposal of a Cost-Effectiveness Modeling Approach for Heart Failure Treatment Assessment: Considering the Short- and Long-Term Impact of Hospitalization on Event Rates
Di Tanna GL; Angell B; Urbich M; Lindgren P; Gaziano TA; Globe G; Stollenwerk B
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2022;23(6):1059-1070
Value appropriation in hepatitis C
Lindgren P; Lofvendahl S; Bradvik G; Weiland O; Jonsson B
Article: EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES. 2022;8(1):31-38
Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden
Landmesser U; Lindgren P; Hagstrom E; Hout BV; Villa G; Pemberton-Ross P; Arellano J; Svensson ME; Sibartie M; Fonarow GC
Article: NEUROLOGY AND THERAPY. 2021;10(2):919-940
Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer's Disease
Herring WL; Gould IG; Fillit H; Lindgren P; Forrestal F; Thompson R; Pemberton-Ross P
Article: JOURNAL OF VIRAL HEPATITIS. 2021;28(1):142-146
Reduced work absenteeism in patients with hepatitis C treated with second-generation direct-acting antivirals
Lindgren P; Lofvendahl S; Bradvik G; Weiland O
Article: DIABETOLOGIA. 2020;63(12):2582-2594
Costs of diabetes complications: hospital-based care and absence from work for 392,200 people with type 2 diabetes and matched control participants in Sweden
Andersson E; Persson S; Hallen N; Ericsson A; Thielke D; Lindgren P; Steen Carlsson K; Jendle J
Journal article: VALUE IN HEALTH. 2020;23:s493
PCV38 The IMPACT on Clinical an Economic VALUE of Patient Prioritization According to Risk: Evolocumab in Patients with Myocardial Infarction in Sweden
Hagström E; Lindgren P; Villa G; Martinez L; Arellano J; Svensson ME; Fonarow GC
Article: BRITISH JOURNAL OF SPORTS MEDICINE. 2020;54(21):1294-1299
A Swedish primary healthcare prevention programme focusing on promotion of physical activity and a healthy lifestyle reduced cardiovascular events and mortality: 22-year follow-up of 5761 study participants and a reference group
Journath G; Hammar N; Vikstrom M; Linnersjo A; Walldius G; Krakau I; Lindgren P; de Faire U; Hellenius M-L
Article: BMC EMERGENCY MEDICINE. 2020;20(1):85
Healthcare pathways and resource use: mapping consequences of ambulance assessment for direct care with alternative healthcare providers
Varg S; Vicente V; Castren M; Lindgren P; Rehnberg C
Article: DIABETES OBESITY & METABOLISM. 2020;22(9):1586-1597
Days absent from work as a result of complications associated with type 2 diabetes: Evidence from 20 years of linked national registry data in Sweden
Persson S; Johansen P; Andersson E; Lindgren P; Thielke D; Thorsted BL; Jendle J; Carlsson KS
Journal article: NATURE REVIEWS UROLOGY. 2020;17(8):482
Author Correction: Introducing PIONEER: a project to harness big data in prostate cancer research.
Omar MI; Roobol MJ; Ribal MJ; Abbott T; Agapow P-M; Araujo S; Asiimwe A; Auffray C; Balaur I; Beyer K; Bernini C; Bjartell A; Briganti A; Butler-Ransohoff J-E; Campi R; Cavelaars M; De Meulder B; Devecseri Z; Voss MD; Dimitropoulos K; Evans-Axelsson S; Franks B; Fullwood L; Horgan D; Smith EJ; Kiran A; Kivinummi K; Lambrecht M; Lancet D; Lindgren P; MacLennan S; MacLennan S; Nogueira MM; Moen F; Moinat M; Papineni K; Reich C; Reiche K; Rogiers S; Sartini C; van Bochove K; van Diggelen F; Van Hemelrijck M; Van Poppel H; Zong J; N'Dow J; PIONEER Consortium
Article: NATURE REVIEWS UROLOGY. 2020;17(6):351-362
Introducing PIONEER: a project to harness big data in prostate cancer research
Omar MI; Roobol MJ; Ribal MJ; Abbott T; Agapow P-M; Araujo S; Asiimwe A; Auffray C; Balaur I; Beyer K; Bernini C; Bjartell A; Briganti A; Butler-Ransohoff J-E; Campi R; Cavelaars M; De Meulder B; Devecseri Z; Voss MD; Dimitropoulos K; Evans-Axelsson S; Franks B; Fullwood L; Horgan D; Smith EJ; Kiran A; Kivinummi K; Lambrecht M; Lancet D; Lindgren P; MacLennan S; MacLennan S; Nogueira MM; Moen F; Moinat M; Papineni K; Reich C; Reiche K; Rogiers S; Sartini C; van Bochove K; van Diggelen F; Van Hemelrijck M; Van Poppel H; Zong J; N'Dow J; Andersson E; Arala H; Auvinen A; Bangma C; Burke D; Cardone A; Casariego J; Cuperus G; Dabestani S; Esperto F; Fossati N; Fridhammar A; Gandaglia G; Tandefelt DG; Horn F; Huber J; Hugosson J; Huisman H; Josefsson A; Kilkku O; Kreuz M; Lardas M; Lawson J; Lefresne F; Lejeune S; Longden-Chapman E; McVie G; Moris L; Mottet N; Murtola T; Nicholls C; Pang KH; Pascoe K; Picozzi M; Plass K; Pohjanjousi P; Reaney M; Remmers S; Robinson P; Schalken J; Schravendeel M; Seisen T; Servan A; Shiranov K; Snijder R; Steinbeisser C; Taibi N; Talala K; Tilki D; Van den Broeck T; Vassilev Z; Voima O; Vradi E; Waldeck R; Weistra W; Willemse P-P; Wirth M; Wolfinger R; Kermani NZ
Article: BMJ OPEN. 2020;10(6):e032573
Time-driven activity-based costing for patients with multiple chronic conditions: a mixed-method study to cost care in a multidisciplinary and integrated care delivery centre at a university-affiliated tertiary teaching hospital in Stockholm, Sweden
Keel G; Muhammad R; Savage C; Spaak J; Gonzalez I; Lindgren P; Guttmann C; Mazzocato P
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(15_suppl):e19051
A comparative study on costs of cancer and access to medicines in Europe.
Wilking NE; Brådvik G; Lindgren P; Svedman C; Jönsson B; Hofmarcher T
Journal article: VALUE IN HEALTH. 2020;23:s172
PIN20 SOCIETAL PRODUCTIVITY GAINS FROM NEW THERAPIES IN HEPATITIS C
Löfvendahl S; Brådvik G; Weiland O; Lindgren P
Article: EUROPEAN JOURNAL OF CANCER. 2020;129:41-49
The cost of cancer in Europe 2018
Hofmarcher T; Lindgren P; Wilking N; Jonsson B
Article: JOURNAL OF MULTIDISCIPLINARY HEALTHCARE. 2019;12:1075-1083
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic
Rafiq M; Keel G; Mazzocato P; Spaak J; Guttmann C; Lindgren P; Savage C
Journal article: VALUE IN HEALTH. 2019;22:s548
PCV40 COST-EFFECTIVENESS OF EVOLOCUMAB IN ATHEROSCLEROTIC CARDIOVASCULAR DISEASE PATIENTS WITH VARYING RISK PROFILES IN SWEDEN
Lindgren P; Hagström E; van Hout B; Villa G; Pemberton-Ross P; Arellano J; Sibartie M; Fonarow GC
Journal article: VALUE IN HEALTH. 2019;22:s685
PMH28 ASSESSING THE LIFE-CYCLE VALUE ADDED OF SECOND-GENERATION ANTIPSYCHOTICS IN SWEDEN AND THE UK: THE CASE OF RISPERIDONE
Berdud M; Bernhardsson NW; Talaya MBZ; Lindgren P; Towse A
Journal article: EUROPEAN HEART JOURNAL. 2019;40(Supplement_1):ehz748.0183
P1225Cost-effectiveness of evolocumab in patients with high atherosclerotic cardiovascular risk in Sweden
Lindgren P; Hagstrom E; Van Hout B; Villa G; Urbich M; Sandelin R; Svensson ME; Fonarow GC
Article: INTERNATIONAL JOURNAL OF HEALTH PLANNING AND MANAGEMENT. 2019;34(4):1439-1455
Exploring staff experience of economic efficiency requirements in health care: A mixed method study
Korlen S; Amer-Wahlin I; Lindgren P; Schwarz UVT
Journal article: JOURNAL OF CLINICAL LIPIDOLOGY. 2019;13(3):e31
An updated cost-effectiveness analysis of evolocumab therapy for reducing cardiovascular events in very high-risk patients with atherosclerotic cardiovascular disease according to the 2018 ACC/AHA guideline
Fonarow GC; van Hout B; Villa G; Arellano J; Lindgren P
Article: INTERNATIONAL JOURNAL FOR QUALITY IN HEALTH CARE. 2019;31(4):276-282
Inter-hospital variations in health outcomes in childbirth care in Sweden: a register-based study
Mesterton J; Brommels M; Ladfors L; Lindgren P; Amer-Wahlin I
Article: DISABILITY AND REHABILITATION. 2019;41(8):966-973
Psychometric properties of the Zarit Caregiver Burden Interview administered to caregivers to patients with Duchenne muscular dystrophy: a Rasch analysis
Landfeldt E; Mayhew A; Straub V; Bushby K; Lochmuller H; Lindgren P
Article: APPLIED HEALTH ECONOMICS AND HEALTH POLICY. 2019;17(1):15-24
Standardized Questionnaire for the Measurement, Valuation, and Estimation of Costs of Informal Care Based on the Opportunity Cost and Proxy Good Method
Landfeldt E; Zethraeus N; Lindgren P
Journal article: INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE. 2019;35(S1):69
PP170 Quantifying the Life-Cycle Value of Second Generation Antipsychotics
Berdud M; Wallin-Bernhardsson N; Zamora B; Lindgren P; Towse A
Article: BMC HEALTH SERVICES RESEARCH. 2018;18(1):963
The development and validation of a scale to explore staff experience of governance of economic efficiency and quality (GOV-EQ) of health care
Korlen S; Richter A; Amer-Wahlin I; Lindgren P; Schwarz UVT
Article: AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV. 2018;30(9):1090-1098
Excess costs of non-infectious comorbidities among people living with HIV - estimates from Denmark and Sweden
Hjalte F; Calara PS; Blaxhult A; Helleberg M; Wallace K; Lindgren P
Article: MUSCLE & NERVE. 2018;58(3):367-373
Psychometric analysis of the pediatric quality of life inventory 3.0 neuromuscular module administered to patients with duchenne muscular dystrophy: A rasch analysis
Landfeldt E; Mayhew A; Straub V; Lochmueller H; Bushby K; Lindgren P
Journal article: EUROPEAN HEART JOURNAL. 2018;39(suppl_1):ehy563.p4389
P4389Favourable long-term effects of a cardiovascular prevention program in primary health care in Sweden in men, and women on first cardiovascular events, cardiovascular mortality, and all-cause mortality
Journath G; Hammar N; Hammar N; Vikstrom M; Linnersjo A; Linnersjo A; Walldius G; Krakau I; Lindgren P; Lindgren P; De Faire U; Hellenius ML
Article: PLOS ONE. 2018;13(6):e0199170
Sociodemographic determinants and health outcome variation in individuals with type 1 diabetes mellitus: A register-based study
Willers C; Iderberg H; Axelsen M; Dahlstrom T; Julin B; Leksell J; Lindberg A; Lindgren P; Muth KL; Svensson A-M; Lilja M
Article: LAKARTIDNINGEN. 2018;115:E399
[Leaders as intermediates between economic incentive models and professional motivation].
Korlén S; Essén A; Lindgren P; Amer-Wåhlin I; von Thiele Schwarz U
Article: DIABETES-METABOLISM RESEARCH AND REVIEWS. 2018;34(4):e2984
Association between sociodemographic determinants and health outcomes in individuals with type 2 diabetes in Sweden
Julin B; Willers C; Leksell J; Lindgren P; Muth KL; Svensson A-M; Lilja M; Dahlstrom T
Article: JAMA CARDIOLOGY. 2017;2(10):1069-1078
Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease
Fonarow GC; Keech AC; Pedersen TR; Giugliano RP; Sever PS; Lindgren P; van Hout B; Villa G; Qian Y; Somaratne R; Sabatine MS
Article: HEALTH SERVICES MANAGEMENT RESEARCH. 2017;30(3):148-155
Professionals' perspectives on a market-inspired policy reform: A guiding light to the blind spots of measurement
Korlen S; Amer-Wahlin I; Lindgren P; Schwarz UVT
Article: ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA. 2017;96(5):597-606
Case mix adjusted variation in cesarean section rate in Sweden
Mesterton J; Ladfors L; Abreu AE; Lindgren P; Saltvedt S; Weichselbraun M; Amer-Wahlin I
Journal article: GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT. 2017;4(1):100-103
Mortality Cost of Duchenne Muscular Dystrophy
Landfeldt E; Eagle M; Straub V; Lochmüller H; Bushby K; Lindgren P
Article: JOURNAL OF HEALTH ORGANIZATION AND MANAGEMENT. 2017;31(2):126-141
Managerial strategies to make incentives meaningful and motivating
Korlen S; Essen A; Lindgren P; Amer-Wahlin I; Schwarz UVT
Article: CLINICAL THERAPEUTICS. 2017;39(4):771-786.e3
Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain
Villa G; Lothgren M; Kutikova L; Lindgren P; Gandra SR; Fonarow GC; Sorio F; Masana L; Bayes-Genis A; van Hout B
Journal article: JOURNAL OF CANCER POLICY. 2017;11:12-18
Assessment of value for resource allocation in cancer care
Lindgren P; Jonsson B; Wilking N
Article: PHARMACOECONOMICS. 2017;35(2):249-258
Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness Analysis
Landfeldt E; Alfredsson L; Straub V; Lochmuller H; Bushby K; Lindgren P
Journal article: GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT. 2017;4(1):grhta.5000260
Mortality cost of Duchenne muscular dystrophy
Landfeldt E; Eagle M; Straub V; Lochmuller H; Bushby K; Lindgren P
Journal article: EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY. 2016;206:e161
Case mix adjusted variation in cesarean section rate in Sweden
Ladfors L; Amer-Wåhlin I; Saltvedt S; Weichselbraun M; Abreu AE; Lindgren P; Mesterton J
Journal article: ANNALS OF ONCOLOGY. 2016;27:vi475
1368P Access to cancer drugs in Europe years 2005-2014
Wilking N; Lindgren P; Wilking U; Jönsson B
Article: EUROPEAN JOURNAL OF CANCER. 2016;66:162-170
The cost and burden of cancer in the European Union 1995-2014
Jonsson B; Hofmarcher T; Lindgren P; Wilking N
Article: JMIR RESEARCH PROTOCOLS. 2016;5(3):e188
A Cluster-Randomized Controlled Trial Evaluating the Effectiveness and Cost-Effectiveness of Tobacco Cessation on Prescription in Swedish Primary Health Care: A Protocol of the Motivation 2 Quit (M2Q) Study.
Leppänen A; Lindgren P; Sundberg CJ; Petzold M; Tomson T
Article: CLINICAL CARDIOLOGY. 2016;39(6):313-320
Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States
Gandra SR; Villa G; Fonarow GC; Lothgren M; Lindgren P; Somaratne R; van Hout B
Article: BMC PREGNANCY AND CHILDBIRTH. 2016;16(1):125
Case mix adjustment of health outcomes, resource use and process indicators in childbirth care: a register-based study
Mesterton J; Lindgren P; Abreu AE; Ladfors L; Lilja M; Saltvedt S; Amer-Wahlin I
Article: DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY. 2016;58(5):508-515
Health-related quality of life in patients with Duchenne muscular dystrophy: a multinational, cross-sectional study
Landfeldt E; Lindgren P; Bell CF; Guglieri M; Straub V; Lochmueller H; Bushby K
Article: JOURNAL OF NEUROLOGY. 2016;263(5):906-915
Quantifying the burden of caregiving in Duchenne muscular dystrophy
Landfeldt E; Lindgren P; Bell CF; Guglieri M; Straub V; Lochmuller H; Bushby K
Article: NEUROMUSCULAR DISORDERS. 2015;25(12):937-944
Development and psychometric analysis of the Duchenne muscular dystrophy Functional Ability Self-Assessment Tool (DMDSAT)
Landfeldt E; Mayhew A; Eagle M; Lindgren P; Bell CF; Guglieri M; Straub V; Lochmueller H; Bushby K
Article: PLOS ONE. 2015;10(11):e0140201
Time Trends in Incidence and Mortality of Acute Myocardial Infarction, and All-Cause Mortality following a Cardiovascular Prevention Program in Sweden
Journath G; Hammar N; Elofsson S; Linnersjo A; Vikstrom M; Walldius G; Krakau I; Lindgren P; de Faire U; Hellenius M-L
Journal article: CIRCULATION. 2015;132(suppl_3)
Abstract 18114: Differences Between Observed and Predicted Cardiovascular Event Rates Using the Framingham and REACH Equations: The Case of High-intensity Statin Users in the United Kingdom
Taylor B; Lothgren M; Villa G; Lindgren P; Van Hout B; Mark D
Article: VALUE IN HEALTH. 2015;18(4):439-448
Determinants of Utility Based on the EuroQol Five-Dimensional Questionnaire in Patients with Chronic Heart Failure and Their Change Over Time: Results from the Swedish Heart Failure Registry
Berg J; Lindgren P; Mejhert M; Edner M; Dahlstrom U; Kahan T
Article: JOURNAL OF NEUROMUSCULAR DISEASES. 2015;2(1):63-72
Compliance to Care Guidelines for Duchenne Muscular Dystrophy.
Landfeldt E; Lindgren P; Bell CF; Schmitt C; Guglieri M; Straub V; Lochmüller H; Bushby K
Journal article: GESUNDHEITSOKONOMIE UND QUALITATSMANAGEMENT. 2014;19(6):263-271
Cost-effectiveness of Dronedarone in Comparison with Relevant Treatment Alternatives in Germany
Nilsson J; Akerborg O; Seifert C; Rosenfeld S; Lindgren P
Article: NEUROLOGY. 2014;83(6):529-536
The burden of Duchenne muscular dystrophy An international, cross-sectional study
Landfeldt E; Lindgren P; Bell CF; Schmitt C; Guglieri M; Straub V; Lochmueller H; Bushby K
Article: THROMBOSIS RESEARCH. 2014;133(2):162-167
Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec registry
Salaj P; Kubes R; Cetkovsky P; Capova I; Penka M; Ovesna P; Mesterton J; Lindgren P
Article: JRSM CARDIOVASCULAR DISEASE. 2014;3:2048004014548735
Health-related quality of life and long-term morbidity and mortality in patients hospitalised with systolic heart failure
Berg J; Lindgren P; Kahan T; Schill O; Persson H; Edner M; Mejhert M
Article: CANADIAN JOURNAL OF CARDIOLOGY. 2013;29(10):1249-1255
Cost-Effectiveness of Dronedarone in Patients With Atrial Fibrillation in the ATHENA Trial
Berg J; Sauriol L; Connolly S; Lindgren P
Journal article: EUROPEAN HEART JOURNAL. 2013;34(suppl_1):p1490
Long-term morbidity and mortality in patients hospitalised with systolic heart failure, and the impact of health-related quality of life
Berg J; Lindgren P; Kahan T; Schill O; Persson H; Edner M; Mejhert M
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2013;14(3):481-493
Cost-effectiveness analysis of dronedarone versus other anti-arrhythmic drugs for the treatment of atrial fibrillation-results for Canada, Italy, Sweden and Switzerland
Nilsson J; Akerborg O; Bego-Le Bagousse G; Rosenquist M; Lindgren P
Article: EUROPEAN JOURNAL OF INTERNAL MEDICINE. 2013;24(3):260-265
Long term health care consumption and cost expenditure in systolic heart failure
Mejhert M; Lindgren P; Schill O; Edner M; Persson H; Kahan T
Journal article: CLINICOECONOMICS AND OUTCOMES RESEARCH. 2013;5:19-28
Cost-effectiveness of dronedarone and standard of care compared with standard of care alone: US results of an ATHENA lifetime model
Reynolds MR; Nilsson J; Akerborg O; Jhaveri M; Lindgren P
Journal article: VALUE IN HEALTH. 2012;15(7):a422
PCN75 Survival and Costs in Metastatic Renal Cell Carcinoma: A Comparison of mRCC Treatment Pre- and Post Tyrosine Kinase Inhibitor (TKI) Introduction Using Retrospective Registry Data
Jönsson L; Sandin R; Lindgren P; Kowalski J; Wahlgren T; Harmenberg U; Sandström P; Ljungberg B; Jakobsson M
Article: CLINICAL THERAPEUTICS. 2012;34(8):1788-1802
Cost-Effectiveness of Dronedarone in Atrial Fibrillation: Results for Canada, Italy, Sweden, and Switzerland
Akerborg O; Nilsson J; Bascle S; Lindgren P; Reynolds M
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2012;13(4):445-450
Cost-effectiveness of statins revisited: lessons learned about the value of innovation
Lindgren P; Jonsson B
Article: PHARMACOECONOMICS. 2012;30(6):513-530
Cost Effectiveness of Quetiapine in Patients with Acute Bipolar Depression and in Maintenance Treatment after an Acute Depressive Episode
Ekman M; Lindgren P; Miltenburger C; Meier G; Locklear JC; Chatterton ML
Article: THROMBOSIS RESEARCH. 2012;129(5):e233-e237
Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: Haemophilia registry data from the Czech Republic
Salaj P; Penka M; Smejkal P; Geierova V; Ovesna P; Brabec P; Cetkovsky P; Kubes R; Mesterton J; Lindgren P
Article: ACTA PSYCHIATRICA SCANDINAVICA. 2011;124(3):214-225
Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder
Kasteng F; Eriksson J; Sennfalt K; Lindgren P
Article: EUROPACE. 2011;13(1):23-30
Predictors of costs related to cardiovascular disease among patients with atrial fibrillation in five European countries
Holstenson E; Ringborg A; Lindgren P; Coste F; Diamand F; Nieuwlaat R; Crijns H
Journal article: VALUE IN HEALTH. 2010;13(7):a355
PCV75 CANADIAN COST-EFFECTIVENESS ANALYSIS OF DRONEDARONE VERSUS OTHER ANTI-ARRHYTMIC DRUGS IN PATIENTS WITH PAROXYSMAL AND PERSISTENT ATRIAL FIBRILLATION
Nilsson J; Åkerborg Ö; Lindgren P; Bascle S
Article: INTERNATIONAL JOURNAL OF CLINICAL PRACTICE. 2010;64(9):1228-1234
The economic consequences of non-adherence to lipid-lowering therapy: results from the Anglo-Scandinavian-Cardiac Outcomes Trial
Lindgren P; Eriksson J; Buxton M; Kahan T; Poulter NR; Dahlof B; Sever PS; Wedel H; Jonsson B
Article: DIABETES & METABOLISM. 2010;36(3):198-203
Time to insulin treatment and factors associated with insulin prescription in Swedish patients with type 2 diabetes
Ringborg A; Lindgren P; Yin DD; Martinell M; Stalhammar J
Article: HAEMOPHILIA. 2010;16(3):487-494
The value of early treatment in patients with haemophilia and inhibitors
Kavakli K; Yesilipek A; Antmen B; Aksu S; Balkan C; Yilmaz D; Kupesiz A; Sasmaz I; Lindgren P; Mesterton J
Article: QUALITY OF LIFE RESEARCH. 2010;19(3):381-390
Factors determining utility measured with the EQ-5D in patients with atrial fibrillation
Berg J; Lindgren P; Nieuwlaat R; Bouin O; Crijns H
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2009;38(6):409-418
Costs and outcomes for patients with rheumatoid arthritis treated with biological drugs in Sweden: a model based on registry data
Kobelt G; Lindgren P; Geborek P
Article: CANADIAN JOURNAL OF CARDIOLOGY. 2009;25(11):e362-e369
Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial
Wagner M; Lindgren P; Merikle E; Goetghebeur M; Joensson B
Article: JOURNAL OF CARDIOVASCULAR RISK. 2009;16(5):576-582
The impact of acute myocardial infarction and stroke on health care costs in patients with type 2 diabetes in Sweden
Ringborg A; Yin DD; Martinell M; Stalhammar J; Lindgren P
Article: INTERNATIONAL JOURNAL OF CLINICAL PRACTICE. 2009;63(7):997-1007
Resource use associated with type 2 diabetes in Asia, Latin America, the Middle East and Africa: results from the International Diabetes Management Practices Study (IDMPS)
Ringborg A; Cropet C; Jonsson B; Gagliardino JJ; Ramachandran A; Lindgren P
Article: ATHEROSCLEROSIS SUPPLEMENTS. 2009;10(1):3-21
Bridging science and health policy in cardiovascular disease: focus on lipid management A Report from a Session held during the 7th International Symposium on Multiple Risk Factors in Cardiovascular Diseases: Prevention and Intervention - Health Policy, in Venice, Italy, on 25 October, 2008
Atella V; Brady A; Catapano AL; Critchley J; Graham IM; Hobbs FDR; Leal J; Lindgren P; Vanuzzo D; Volpe M; Wood D; Paoletti R
Article: MULTIPLE SCLEROSIS JOURNAL. 2009;15(6):741-751
The long-term cost of multiple sclerosis in France and potential changes with disease-modifying interventions
Kobelt G; Texier-Richard B; Lindgren P
Article: INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE. 2009;25(2):181-189
Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden
Lindgren P; Geborek P; Kobelt G
Article: ALLERGY. 2009;64(3):431-438
An economic evaluation of NIOX MINO airway inflammation monitor in the United Kingdom
Price D; Berg J; Lindgren P
Journal article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2009;:1-10
Costs and outcomes for patients with rheumatoid arthritis treated with biological drugs in Sweden: a model based on registry data
Kobelt G; Lindgren P; Geborek P
Article: PHARMACOECONOMICS. 2009;27(3):221-230
The Lifetime Cost Effectiveness of Amlodipine-Based Therapy Plus Atorvastatin Compared with Atenolol Plus Atorvastatin, Amlodipine-Based Therapy Alone and Atenolol-Based Therapy Alone Results from ASCOT
Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlof B; Sever PS; Wedel H; Jonsson B
Article: DIABETIC MEDICINE. 2008;25(10):1178-1186
Prevalence and incidence of Type 2 diabetes and its complications 1996-2003 -: estimates from a Swedish population-based study
Ringborg A; Lindgren P; Martinell M; Yin DD; Schon S; Stalhammar J
Article: MULTIPLE SCLEROSIS JOURNAL. 2008;14(5):679-690
Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden
Kobelt G; Berg J; Lindgren P; Jonsson B; Stawiarz L; Hillert J
Article: INTERNATIONAL JOURNAL OF CLINICAL PRACTICE. 2008;62(5):708-716
Resource use and costs of type 2 diabetes in Sweden -: estimates from population-based register data
Ringborg A; Martinell M; Stalhammar J; Yin DD; Lindgren P
Article: EUROPACE. 2008;10(4):403-411
Costs of atrial fibrillation in five European countries:: results from the Euro Heart Survey on atrial fibrillation
Ringborg A; Nieuwlaat R; Lindgren P; Joensson B; Fidan D; Maggioni AP; Lopez-Sendon J; Stepinska J; Cokkinos DV; Crijns HJGM
Article: JOURNAL OF CARDIOVASCULAR RISK. 2008;15(2):230-233
Utility loss and indirect costs after stroke in Sweden
Lindgren P; Glader E-L; Jonsson B
Article: RESPIRATORY MEDICINE. 2008;102(2):219-231
Economic evaluation of FE_NO measurement in diagnosis and 1-year management of asthma in Germany
Berg J; Lindgren P
Article: INTERNATIONAL JOURNAL OF CLINICAL PRACTICE. 2007;61(8):1410-1414
Determinants of cholesterol goal attainment at 12 months in patients with hypercholesterolaemia not at consensus goal after 3 months of treatment with lipid-lowering drugs
Lindgren P; Borgstrom F; Stalhammar J; Alemao E; Jonsson L
Article: EUROPEAN HEART JOURNAL. 2007;28(12):1448-1453
Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin
Lindgren P; Graff J; Olsson AG; Pedersen TJ; Jonsson B
Article: CLINICAL THERAPEUTICS. 2007;29(6):1184-1202
Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation:: A European model based on the CLARITY and COMMIT trials
Berg J; Lindgren P; Spiesser J; Parry D; Jonsson B
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2007;8(1):51-57
Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany
Brueggenjuergen B; Lindgren P; Ehlken B; Rupprecht H-J; Willich SN
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2007;8(1):25-30
Utility loss and indirect costs following cardiovascular events in hypertensive patients:: the ASCOT health economic substudy
Lindgren P; Kahan T; Poulter N; Buxton M; Svarvar P; Dahlof B; Jonsson B
Article: INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE. 2007;23(2):177-183
Lifestyle intervention to prevent diabetes in men and women with impaired glucose tolerance is cost-effective
Lindgren P; Lindstrom J; Tuomilehto J; Uusitupa M; Peltonen M; Jonsson B; de Faire U; Hellenius M-L
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2006;7 Suppl 2:5-13
Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis.
Kobelt G; Berg J; Lindgren P; Jönsson B
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2006;7 Suppl 2:55-64
Costs and quality of life in multiple sclerosis in The Netherlands.
Kobelt G; Berg J; Lindgren P; Anten B; Ekman M; Jongen PJH; Polman C; Uitdehaag B
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2006;7 Suppl 2:75-85
Costs and quality of life of multiple sclerosis in Sweden.
Berg J; Lindgren P; Fredrikson S; Kobelt G
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2006;7 Suppl 2:96-104
Costs and quality of life of multiple sclerosis in the United Kingdom.
Kobelt G; Berg J; Lindgren P; Kerrigan J; Russell N; Nixon R
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2006;7 Suppl 2:65-74
Costs and quality of life of multiple sclerosis in Spain.
Kobelt G; Berg J; Lindgren P; Izquierdo G; Sánchez-Soliño O; Pérez-Miranda J; Casado MA; Associación Española de Esclerosis Múltiple
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2006;7 Suppl 2:14-23
Costs and quality of life of multiple sclerosis in Austria.
Kobelt G; Berg J; Lindgren P; Plesnilla C; Baumhackl U; Berger T; Kolleger H; Vass K
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2006;7 Suppl 2:86-95
Costs and quality of life of multiple sclerosis in Switzerland.
Kobelt G; Berg J; Lindgren P; Gerfin A; Lutz J
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2006;7 Suppl 2:34-44
Costs and quality of life of multiple sclerosis in Germany.
Kobelt G; Berg J; Lindgren P; Elias WG; Flachenecker P; Freidel M; König N; Limmroth V; Straube E
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2006;7 Suppl 2:45-54
Costs and quality of life of multiple sclerosis in Italy.
Kobelt G; Berg J; Lindgren P; Battaglia M; Lucioni C; Uccelli A
Article: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 2006;77(8):918-926
Costs and quality of life of patients with multiple sclerosis in Europe
Kobelt G; Berg J; Lindgren P; Fredrikson S; Jonsson B
Journal article: PHARMACOECONOMICS - SPANISH RESEARCH ARTICLES. 2006;3(3):123-135
Coste-efectividad de atorvastatina en hipertensos con riesgo moderado: evaluación económica del estudio ASCOT-LLA
Gómez CC; de Bobadilla JF; Vargas MG; Lindgren P; Jönsson B
Article: JOURNAL OF CARDIOVASCULAR RISK. 2005;12(6):530-534
Association between achieving treatment goals for lipid-lowering and cardiovascular events in real clinical practice
Lindgren P; Borgström F; Stålhammar J; Alemao E; Yin DDP; Jönsson L
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2005;6(4):354-362
The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial.
Ringborg A; Lindgren P; Jönsson B
Article: RHEUMATOLOGY. 2005;44(9):1169-1175
Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis
Kobelt G; Lindgren P; Lindroth Y; Jacobson L; Eberhardt K
Article: ANNALS OF THE RHEUMATIC DISEASES. 2005;64(8):1174-1179
Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial
Kobelt G; Lindgren P; Singh A; Klareskog L
Article: EUROPEAN JOURNAL OF NEUROLOGY. 2005;12:68-73
Cost of Parkinson's disease in Europe
Lindgren P; von Campenhausen S; Spottke E; Siebert U; Dodel R
Journal article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2005;12(1):29-36
Cost-Effectiveness of Atorvastatin for the Prevention of Coronary and Stroke Events: An Economic Analysis of the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA)
Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B
Article: JOURNAL OF CARDIOVASCULAR RISK. 2005;12(1):29-36
Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm (ASCOT-LLA)
Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B
Article: CLINICAL THERAPEUTICS. 2005;27(1):100-110
The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden
Lindgren P; Stenestrand U; Malmberg K; Jönsson B
Article: JOURNAL OF CARDIOVASCULAR RISK. 2004;11(6):460-465
The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study
Lamy A; Jönsson B; Weintraub WS; Zhao F; Chrolavicius S; Bakhai A; Culler S; Gafni A; Lindgren P; Mahoney E; Yusuf S
Article: JOURNAL OF INTERNAL MEDICINE. 2004;255(5):562-570
Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden:: a long-term model based on the cure trial
Lindgren P; Jönsson B; Yusuf S
Journal article: PHARMACOECONOMICS - GERMAN RESEARCH ARTICLES. 2004;2(1):31-41
Die Langzeit-Kosteneffektivität von Clopidogrel zusätzlich zu Azetylsalizylsäure bei Patienten mit akutem Koronarsyndrom ohne ST-Streckenhebung im österreichischen Gesundheitssystem
Schwarz B; Lindgren P; Nanz S
Article: PREVENTIVE MEDICINE. 2003;36(4):403-409
Cost-effectiveness of primary prevention of coronary heart disease through risk factor intervention in 60-year-old men from the county of Stockholm -: a stochastic model of exercise and dietary advice
Lindgren P; Fahlstadius P; Hellenius ML; Jönsson B; de Faire U
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2003;4(1):37-42
The cost-effectiveness of early cabergoline treatment compared to levodopa in Sweden.
Lindgren P; Jönsson B; Duchane J
Article: ARTHRITIS & RHEUMATOLOGY. 2002;46(9):2310-2319
Modeling the progression of rheumatoid arthritis - A two-country model to estimate costs and consequences of rheumatoid arthritis
Kobelt G; Jönsson L; Lindgren P; Young A; Eberhardt K
Journal article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2002;3(3):180-187
Modelling the costs and effects of leflunomide in rheumatoid arthritis.
Kobelt G; Lindgren P; Young A
Article: PHARMACOECONOMICS. 2002;20(2):101-108
Cost-effectiveness analysis of exemestane compared with Megestrol in advanced breast cancer -: A model for Europe and Australia
Lindgren P; Jönsson B; Redaelli A; Radice D
Journal article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2001;2(2):60-68
Costs and quality of life in multiple sclerosis
Kobelt G; Lindgren P; Smala A; Bitsch A; Haupts M; Kölmel HW; König N; Rieckmann P; Zettl UK; the German Cost of MS Study Group
Article: PHARMACOECONOMICS. 1999;16(4):409-416
Costs of mini mental state examination-related cognitive impairment
Jönsson L; Lindgren P; Wimo A; Jönsson B; Winblad B
Article: CLINICAL THERAPEUTICS. 1999;21(7):1230-1240
The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease:: A Markov model
Jönsson L; Lindgren P; Wimo A; Jönsson B; Winblad B
Show more

All other publications

Review: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2025;91:56-66
Sex-stratified mortality estimates in people with schizophrenia: A systematic review and meta-analysis of cohort studies of 2,700,825 people with schizophrenia
Solmi M; Croatto G; Fabiano N; Wong S; Gupta A; Fornaro M; Schneider LK; Rohani-Montez SC; Fairley L; Smith N; Bitter I; Gorwood P; Taipale H; Tiihonen J; Cortese S; Dragioti E; Du Rietz E; Nielsen RE; Firth J; Fusar-Poli P; Hartman C; Holt RIG; Hoye A; Koyanagi A; Larsson H; Lehto K; Lindgren P; Manchia M; Nordentoft M; Skonieczna-Zydecka K; Stubbs B; Vancampfort D; Vieta E; De Prisco M; Boyer L; Hojlund M; Correll CU
Review: EUROPEAN UROLOGY. 2024;86(5):400-408
Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe.
Vynckier P; Annemans L; Raes S; Amrouch C; Lindgren P; Májek O; Beyer K; Leenen RCA; Venderbos LDF; Denijs F; van Harten MJ; Helleman J; Chloupková R; Briers E; Vasilyeva V; Rivas JG; Basu P; Chandran A; van den Bergh RCN; Collen S; Van Poppel H; Roobol MJ; Members of the PRAISE-U Consortium
Review: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2024;88:6-20
Effects of antipsychotic treatment on cardio-cerebrovascular related mortality in schizophrenia: A subanalysis of a systematic review and meta-analysis with meta-regression of moderators
Solmi M; Croattog G; Gupta A; Fabianoa N; Wong S; Fornaro M; Schneiderl LK; Rohani-Montez SC; Fairleyl L; Smithl N; Bitterm I; Gorwoodn P; Taipalep H; Tiihonenp J; Cortese S; Dragioti E; Du Rietz E; Nielsen RE; Firth J; Fusar-Poli P; Hartman C; Holt RIG; Hoye A; Koyanagi A; Larsson H; Lehto K; Lindgren P; Manchia M; Nordentoft M; Skonieczna-Zydecka K; Stubbs B; Vancampfortay D; De Prisco M; Boyer L; Vieta E; Correlle CU
Review: EXPERT OPINION ON DRUG SAFETY. 2024;23(10):1249-1269
Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review
Solmi M; Miola A; Capone F; Pallottino S; Hojlund M; Firth J; Siskind D; Holt RIG; Corbeil O; Cortese S; Dragioti E; Du Rietz E; Nielsen RE; Nordentoft M; Fusar-Poli P; Hartman CA; Hoye A; Koyanagi A; Larsson H; Lehto K; Lindgren P; Manchia M; Skonieczna-Zydecka K; Stubbs B; Vancampfort D; Vieta E; Taipale H; Correll CU
Review: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2024;80:55-69
Regional differences in mortality risk and in attenuating or aggravating factors in schizophrenia: A systematic review and meta-analysis
Solmi M; Croatto G; Fornaro M; Schneider LK; Rohani-Montez SC; Fairley L; Smith N; Bitter I; Gorwood P; Taipale H; Tiihonen J; Cortese S; Dragiotiu E; Du Rietz E; Nielsen RE; Firth J; Fusar-Poli P; Hartman C; Holt RIG; Hoye A; Koyanagi A; Larsson H; Lehto K; Lindgren P; Manchia M; Nordentoft M; Skonieczna-Zydecka K; Stubbs B; Vancampfort D; Boyer L; De Prisco M; Vieta E; Correll CU
Conference publication: VALUE IN HEALTH. 2023;26(12):S196-S197
COST-EFFECTIVENESS OF RENAL DENERVATION FOR UNCONTROLLED HYPERTENSION: AN ANALYSIS FOR SWEDEN BASED ON THE SPYRAL HTN-ON MED TRIAL AND OTHER CONTEMPORARY EVIDENCE
Kahan T; Johansen ML; Ryschon AM; Cao K; Kolovetsios M; Lindgren P; Pietzsch J
Letter: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2023;24(3):483
Reply to: making the rules make sense: valuation of constrained resources
Lindgren P
Conference publication: VALUE IN HEALTH. 2022;25(12):S156
A GLOBAL ANALYSIS OF THE VALUE OF PRECISION MEDICINE IN ONCOLOGY - THE CASE OF NON-SMALL CELL LUNG CANCER
Hofmarcher T; Malmberg C; Lindgren P
Editorial comment: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2022;23(8):1259-1261
Breaking the rules: decision-making under absolute resource constraints
Lindgren P
Conference publication: ANNALS OF ONCOLOGY. 2021;32:S1025
Diagnosed with non-small cell lung cancer but not treated
Hofmarcher T; Wilking N; Lindgren P
Editorial comment: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2021;22(6):851-854
Something borrowed, something new: measuring hospital performance in the context of value based health care
Lindgren P; Althin R
Conference publication: VALUE IN HEALTH. 2020;23:S493
THE IMPACT ON CLINICAL AN ECONOMIC VALUE OF PATIENT PRIORITIZATION ACCORDING TO RISK: EVOLOCUMAB IN PATIENTS WITH MYOCARDIAL INFARCTION IN SWEDEN
Hagstrom E; Lindgren P; Villa G; Martinez L; Arellano J; Svensson EM; Fonarow GC
Conference publication: ATHEROSCLEROSIS. 2020;315:E36
COST-EFFECTIVENESS OF EVOLOCUMAB IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA IN BELGIUM
Descamps OS; Van Hout B; Lindgren P; Villa G; Urbich M; Fonarow GC
Conference publication: ANNALS OF ONCOLOGY. 2020;31:S1197
A comparative study on costs of cancer and access to medicines in Europe
Wilking N; Bradvik G; Lindgren P; Svedman C; Jonsson B; Hofmarcher T
Conference publication: DIABETOLOGIA. 2020;63(SUPPL 1):S121
Costs of diabetes complications: hospital based care and production loss for 392,200 people with type 2 diabetes and matched controls in Sweden
Carlsson KS; Andersson E; Persson S; Hallen N; Ericsson A; Thielke D; Lindgren P; Jendle J
Conference publication: DIABETES. 2020;69
Costs of Diabetes Complications: Hospital-Based Care and Production Loss for 392,200 People with Type 2 Diabetes and Matched Controls
Andersson E; Persson S; Hallen N; Ericsson A; Thielke D; Lindgren P; Carlsson KS; Jendle JH
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(15):s1197
A comparative study on costs of cancer and access to medicines in Europe.
Wilking NE; Bradvik G; Lindgren P; Svedman C; Jonsson B; Hofmarcher T
Conference publication: VALUE IN HEALTH. 2020;23:S172
SOCIETAL PRODUCTIVITY GAINS FROM NEW THERAPIES IN HEPATITIS C
Lofvendahl S; Bradvik G; Weiland O; Lindgren P
Review: HEALTH POLICY. 2020;124(4):404-410
Risk sharing in managed entry agreements-A review of the Swedish experience
Andersson E; Svensson J; Persson U; Lindgren P
Conference publication: VALUE IN HEALTH. 2019;22:S548
COST-EFFECTIVENESS OF EVOLOCUMAB IN ATHEROSCLEROTIC CARDIOVASCULAR DISEASE PATIENTS WITH VARYING RISK PROFILES IN SWEDEN
Lindgren P; Hagstrom E; van Hout B; Villa G; Pemberton-Ross P; Arellano J; Sibartie M; Fonarow GC
Conference publication: VALUE IN HEALTH. 2019;22:S685
ASSESSING THE LIFE-CYCLE VALUE ADDED OF SECOND-GENERATION ANTIPSYCHOTICS IN SWEDEN AND THE UK: THE CASE OF RISPERIDONE
Berdud M; Bernhardsson WN; Talaya ZMB; Lindgren P; Towse A
Conference publication: EUROPEAN HEART JOURNAL. 2019;40:681
Cost-effectiveness of evolocumab in patients with high atherosclerotic cardiovascular risk in Sweden
Lindgren P; Hagstrom E; Van Hout B; Villa G; Urbich M; Sandelin R; Svensson ME; Fonarow GC
Published conference paper: JAMA CARDIOLOGY. 2019;4(7):691-695
Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease
Fonarow GC; van Hout B; Villa G; Arellano J; Lindgren P
Letter: ORPHANET JOURNAL OF RARE DISEASES. 2019;14(1):75
Incomplete description of the current body of evidence of the health economics of Duchenne muscular dystrophy
Landfeldt E; Lochmueller H; Lindgren P
Conference publication: EUROPEAN HEART JOURNAL. 2018;39:879
Favourable long-term effects of a cardiovascular prevention program in primary health care in Sweden in men, and women on first cardiovascular events, cardiovascular mortality, and all-cause mortality
Journath G; Hammar N; Hammar N; Vikstrom M; Linnersjo A; Linnersjo A; Walldius G; Krakau I; Lindgren P; De Faire U; Hellenius ML
Conference publication: INTERNATIONAL JOURNAL OF INTEGRATED CARE. 2018;18:61
Social and economic impact of a case management approach for people with rare and complex conditions in Salaj, Romania
Sparring V; Tschank J; Handler K; Mansoory E; Konzett-Smoliner S; Lindgren P
Letter: NEUROMUSCULAR DISORDERS. 2018;28(1):100
Compliance to care guidelines for Duchenne muscular dystrophy in Italy
Landfeldt E; Lindgren P; Guglieri M; Lochmuller H; Bushby K
Review: JOURNAL OF NEUROMUSCULAR DISEASES. 2017;4(4):285-292
Patient Preferences for Treatments of Neuromuscular Diseases: A Systematic Literature Review.
Landfeldt E; Edström J; Lindgren P; Lochmüller H
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2017;35:6535
Does access to cancer drugs relate to survival benefit? A European study in countries with different economic status.
Wilking NE; Jonsson B; Lindgren P; Wilking U
Conference publication: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2017;69(11):1852
OBSERVED VERSUS PREDICTED CARDIOVASCULAR EVENT RATES IN PRIMARY PREVENTION DIABETIC PATIENTS RECEIVING HIGH-INTENSITY STATINS IN THE UNITED KINGDOM
Danese M; Villa G; Taylor B; Lindgren P; Van Hout B; Lothgren M
Review: PHARMACOECONOMICS. 2017;35(3):297-318
A Systematic Review of Cardiovascular Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering Therapies
Wei C-Y; Quek RGW; Villa G; Gandra SR; Forbes CA; Ryder S; Armstrong N; Deshpande S; Duffy S; Kleijnen J; Lindgren P
Conference publication: VALUE IN HEALTH. 2016;19(7):A651-A652
COST-EFFECTIVENESS OF EVOLOCUMAB IN PATIENTS WITH HIGH CARDIOVASCULAR RISK IN SPAIN
Villa G; Lothgren M; Kutikova L; Lindgren P; Gandra SR; Fonarow GC; Sorio F; Masana L; Bayes-Genis A; van Hout B
Conference publication: VALUE IN HEALTH. 2016;19(7):A524
ESTIMATING THE ECONOMIC BURDEN ASSOCIATED WITH THE EARLY STAGES OF PROGRESSION OF ALZHEIMER'S DISEASE IN EUROPE
Lindgren P; Jonsson L; Coste F; Chan E; Bosshard R
Conference publication: ANNALS OF ONCOLOGY. 2016;27
Access to cancer drugs in Europe years 2005-2014
Wilking N; Lindgren P; Wilking U; Jonsson B
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2016;34(15):e18015
Access to cancer drugs in Europe years 2005-2014
Wilking NE; Lindgren P; Wilking U; Jonsson B
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2016;34(15):6620
Is there a link between value as defined by ESMO-MCBS and uptake of new drugs?
Lindgren P; Jonsson B; Hofmarcher T; Wilking NE
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2016;34(15):6618
The burden and direct cost of cancer in Europe (EU-28)
Wilking NE; Hofmarcher T; Lindgren P; Jonsson B
Conference publication: VALUE IN HEALTH. 2016;19(3):A3
COST-EFFECTIVENESS OF LDL-C LOWERING WITH EVOLOCUMAB IN PATIENTS WITH HIGH CARDIOVASCULAR RISK IN THE UNITED STATES
Gandra SR; Villa G; Fonarow G; Lothgren M; Lindgren P; Somaratne R; van Hout B
Corrigendum: NEUROMUSCULAR DISORDERS. 2016;26(4-5):329
Development and psychometric analysis of the Duchenne muscular dystrophy Functional Ability Self-Assessment Tool (DMDSAT) (vol 25, pg 937, 2015)
Landfeldt E; Mayhew A; Eagle M; Lindgren P; Bell CF; Guglieri M; Straub V; Lochmiiller H; Bushby K
Conference publication: VALUE IN HEALTH. 2015;18(7):A569
ASSESSING THE ESMO MAGNITUDE OF CLINICAL BENEFIT SCALE FROM A HEALTH ECONOMICS PERSPECTIVE
Lindgren P; Jonsson B; Wilking N
Conference publication: DIABETOLOGIA. 2015;58:S140-S141
Determinants of HbA_1c in patients with type 1 diabetes in seven Swedish county councils
Lilja M; Julin B; Andersson G; Andersson I-L; Axelsen M; Ek M; Kristiansson R; Lekell J; Lindberg A; Lindgren P; Londahl F; Muth KL; Svensson A-M; Dahlstrom T
Conference publication: EUROPEAN HEART JOURNAL. 2015;36:1201
Long-term effects of a cardiovascular prevention program in primary health care in Sweden
Journath G; Hammar N; Linnersjo A; Vikstrom M; Walldius G; Krakau I; Lindgren P; De Faire U; Hellenius M-L
Conference publication: VALUE IN HEALTH. 2015;18(3):A145
DETERMINANTS OF UTILITY BASED ON THE EQ-5D IN CHRONIC HEART FAILURE PATIENTS AND THEIR CHANGE OVER TIME: RESULTS FROM THE SWEDISH HEART FAILURE REGISTRY
Berg J; Lindgren P; Mejhert M; Edner M; Dahlstrom U; Kahan T
Meeting abstract: VALUE IN HEALTH. 2014;17(7):A558
DETERMINISTIC VERSUS STOCHASTIC PREDICTION OF RISK FOR CARDIOVASCULAR EVENTS
Villa G; Lothgren M; Gandra SR; Lindgren P; van Hout B
Conference publication: NEUROMUSCULAR DISORDERS. 2014;24(9-10):853
The burden of Duchenne muscular dystrophy: An international, cross-sectional study
Landfeldt E; Lindgren P; Bell CF; Schmitt C; Guglieri M; Straub V; Lochmuller H; Bushby K
Conference publication: EUROPEAN JOURNAL OF HEART FAILURE. 2014;16:347
Health-related quality of life in chronic heart failure patients in Sweden: results from the Swedish Heart Failure Registry
Berg J; Mejhert M; Lindgren P; Edner M; Dahlstrom U; Kahan T
Conference publication: EUROPEAN HEART JOURNAL. 2013;34:287
Long-term morbidity and mortality in patients hospitalised with systolic heart failure, and the impact of health-related quality of life
Berg J; Lindgren P; Kahan T; Schill O; Persson H; Edner M; Mejhert M
Conference publication: VALUE IN HEALTH. 2012;15(7):A551
LONG-TERM EFFECTS ON COSTS AND QUALITY ADJUSTED LIFE YEARS OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS TREATED WITH LAQUINIMOD: RESULTS BASED ON THE ALLEGRO AND BRAVO TRIALS
Lang A; Tuomari A; Kobelt G; Lindgren P
Conference publication: VALUE IN HEALTH. 2012;15(7):A422
SURVIVAL AND COSTS IN METASTATIC RENAL CELL CARCINOMA: A COMPARISON OF MRCC TREATMENT PRE- AND POST TYROSINE KINASE INHIBITOR (TKI) INTRODUCTION USING RETROSPECTIVE REGISTRY DATA
Jonsson L; Sandin R; Lindgren P; Kowalski J; Wahlgren T; Harmenberg U; Sandstrom P; Ljungberg B; Jakobsson M
Conference publication: VALUE IN HEALTH. 2012;15(4):A122
COST-EFFECTIVENESS OF DRONEDARONE IN NON-PERMANENT ATRIAL FIBRILLATION IN TURKEY COMPARED TO STANDARD TREATMENT, AMIODARONE AND SOTALOL
Sahin T; Nilsson J; Akerborg O; Lindgren P; Yesil A; Topcu T
Meeting abstract: VALUE IN HEALTH. 2011;14(7):A317
COST OFFSETS AND GAINS IN HEALTH EFFECTS IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS WITH LAQUINIMOD: AN ANALYSIS BASED ON THE ALLEGRO TRIAL
Ekman M; White RE; Buck PE; Justo N; Lindgren P
Conference publication: VALUE IN HEALTH. 2011;14(3):A112-A113
A NET BENEFIT FRAMEWORK (NBF) ANALYSIS OF CHART DATA FOR HAEMOPHILIA INHIBITOR PATIENTS
Weatherall J; Mesterton J; Lindgren P; Dalen J
Conference publication: VALUE IN HEALTH. 2011;14(3):A14-A15
ANALYZING THE EUROPEAN EXTERNAL REFERENCE PRICING SYSTEM USING SPECTRAL GRAPH THEORY
Lindgren P; Akerborg O
Conference publication: EUROPEAN HEART JOURNAL. 2010;31:227
Canadian cost-effectiveness analysis of dronedarone in patients with atrial fibrillation based on the ATHENA trial
Berg J; Sauriol L; Lindgren P
Meeting abstract: VALUE IN HEALTH. 2010;13(3):A58
RESOURCE CONSUMPTION AND COSTS OF CARE THE YEAR BEFORE AND AFTER INITIATION OF INSULIN THERAPY IN SWEDISH PATIENTS WITH TYPE 2 DIABETES
Pettersson B; Lindgren P; Ringborg A; Martinell M; Stalhammar J
Conference publication: CIRCULATION. 2009;120(18):S484-S485
The Economic Consequences of Non-Adherence to Lipid-Lowering Therapy: Results From the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
Lindgren P; Eriksson J; Buxton M; Kahan T; Poulter NR; Dahlof B; Sever PS; Wedel H; Jonsson B
Meeting abstract: VALUE IN HEALTH. 2009;12(7):A335
DRONEDARONE IN ATRIAL FIBRILLATION: MODELING HEALTH OUTCOMES
Akerborg O; Bascle S; Lindgren P
Review: VALUE IN HEALTH. 2009;12(6):857-871
Cost-Utility Analysis of Eprosartan Compared to Enalapril in Primary Prevention and Nitrendipine in Secondary Prevention in Europe-The HEALTH Model
Schwander B; Gradl B; Zoellner Y; Lindgren P; Diener H-C; Lueders S; Schrader J; Antonanzas Villar F; Greiner W; Jonsson B
Review: JOURNAL OF CARDIOVASCULAR RISK. 2009;16(2):138-143
From 4S to IDEAL: the health economics of the statin trials
Lindgren P; Jonsson B
Meeting abstract: VALUE IN HEALTH. 2008;11(6):A548
COST-EFFECTIVENESS OF RITUXIMAB AS SECOND-LINE BIOLOGICAL TREATMENT COMPARED TO REGISTRY DATA
Kobelt G; Lindgren P
Meeting abstract: VALUE IN HEALTH. 2008;11(6):A410
FACTORS DETERMINING UTILITY MEASURED WITH THE EQ-5D IN PATIENTS WITH ATRIAL FIBRILLATION
Berg J; Lindgren P; Nieuwlaat R; Bascle S; Crijns H
Conference publication: DIABETOLOGIA. 2008;51:S425
Resource use associated with type 2 diabetes in 24 countries in Asia, Latin America, the Middle East and Africa
Mechiche S; Ringborg A; Lindgren P; Bengt J; Ramachandran A; Gagliardino JJ
Published conference paper: CURRENT MEDICAL RESEARCH AND OPINION. 2008;24(7):2089-2101
Cost-effectiveness of clopidogrel treatment in percutaneous coronary intervention: a European model based on a meta-analysis of the PCI-CURE, CREDO and PCI-CLARITY trials
Berg J; Fidan D; Lindgren P
Editorial comment: HEART. 2008;94(2):e4
Economic evaluation of ASCOT-BPLA:: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen
Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlof B; Sever PS; Wedel H; Jonsson B
Conference publication: THORAX. 2007;62:A131
Economic evaluation of a new airway inflammation monitor in the diagnosis and management of asthma in the UK
Berg J; Lindgren P
Meeting abstract: VALUE IN HEALTH. 2007;10(6):A414
Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation - A European model based on the clarity and commit trials: Adaptation to Hungary
Berg J; Odhiambo R; Lindgren P
Meeting abstract: VALUE IN HEALTH. 2007;10(6):A239-A240
Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared to current standard practice in Sweden
Kobelt G; Berg J; Lindgren P; Hillert J
Conference publication: VALUE IN HEALTH. 2007;10(6):A385-A386
Economic evaluation of interferon-Å-1b in the treatment of patients with a clinically isolated syndrome (CIS)
Kobelt G; Lindgren P; Miltenburger C; Hillert J
Conference publication: VALUE IN HEALTH. 2007;10(6):A419
Economic evaluation of 80 mg atorvastatin compared to 20-40 mg simvastatin in patients with acute coronary syndromes
Lindgren P; Olsson AG; Pedersen T; Joensson B
Conference publication: VALUE IN HEALTH. 2007;10(6):A410
Health insurance costs of stroke hospital treatments in Hungary; 2003-2005
Karpati K; Boncz I; Lindgren P; Ekman M; Brodszky V; Majer I; Bereczki D; Gulacsi L
Conference publication: VALUE IN HEALTH. 2007;10(6):A237-A238
The cost-effectiveness (cost-utility) of eprosartan in hypertensive patients with cerebrovascular disease in Belgium, Germany, Spain, United Kingdom, and Sweden
Schwander B; Lindgren P; Gradl B
Corrigendum: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2007;8(4):359
Costs and quality of life in multiple sclerosis in The Netherlands (vol 7, pg S55, 2006)
Kobelt G; Berg J; Lindgren P; Anten B; Ekman M; Jongen PJH; Polman C; Uitdehaag B
Conference publication: CIRCULATION. 2007;116(16):793
Cost-effectiveness of clopidogrel in percutaneous coronary intervention based on a meta-analysis of PCI-CURE, CREDO and PCI-CLARITY
Berg J; Fidan D; Jackson J; Lindgren P
Conference publication: EUROPEAN HEART JOURNAL. 2007;28:857
Amlodipine plus atorvastatin is cost-effective compared to atenolol plus atorvastatin, amlodipine or atenolol alone: The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
Lindgren P; Buxton M; Kahan T; Poulter N; Dahlof B; Sever PS; Wedel H; Jonsson B
Review: EUROPEAN HEART JOURNAL SUPPLEMENTS. 2007;9(C):C3-C74
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text
Ryden L; Standl E; Bartnik M; Van den Berghe G; Betteridge J; de Boer M-J; Cosentino F; Jonsson B; Laakso M; Malmberg K; Priori S; Ostergren J; Tuomilehto J; Thrainsdottir I; Vanhorebeek I; Stramba-Badiale M; Lindgren P; Qiao Q; Priori SG; Blanc J-J; Budaj A; Camm J; Dean V; Deckers J; Dickstein K; Lekakis J; McGregor K; Metra M; Morais J; Osterspey A; Tamargo J; Luis Zamorano J; Deckers JW; Bertrand M; Charbonnel B; Erdmann E; Ferrannini E; Flyvbjerg A; GohIke H; Gonzalez Juanatey JR; Graham I; Monteiro PF; Parhofer K; Pyorala K; Raz I; Schernthaner G; Volpe M; Wood D
Conference publication: JOURNAL OF HYPERTENSION. 2007;25:S137
An amlodipine-based regimen is cost-effective compared to an atenolol-based regimen:: Results from the Anglo-Scandinavian cardiac outcomes trial
Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlof B; Sever PS; Wedel H; Jonsson B
Meeting abstract: ATHEROSCLEROSIS SUPPLEMENTS. 2007;8(1):197-198
Trial based economic evaluation of intensive atorvastatin compared to standard simvastatin in the IDEAL trial
Lindgren P; Jonsson B
Conference publication: DIABETES. 2007;56:A156-A157
Time to insulin treatment and factors influencing prescription in Swedish type 2 diabetics
Ringborg A; Lindgren P; Yin DD; Martinell M; Stalhammar J
Conference publication: CIRCULATION. 2007;115(21):E568
Cost-effectiveness of multi-drug regimen of amlodipine plus atorvastatin based on the anglo-scandinavian cardiac outcomes trial (ASCOT):: An economic sub-analysis
Koren M; Lindgren P; Buxton M; Kahan T; Poulter N; Dahlof B; Sever P; Wedel H; Tang SS; Jonsson B
Meeting abstract: VALUE IN HEALTH. 2007;10(3):A110
Economic evaluation of a new airway inflammation monitor in the diagnosis and management of asthma in the US
Berg J; Lindgren P
Meeting abstract: VALUE IN HEALTH. 2007;10(3):A64
Determination of health care costs incurred by swedish patients with type 2 diabetes
Ringborg A; Stalhammar J; Martinell D; Lindgren P
Conference publication: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2007;49(9):392A
Economic evaluation of the anglo-Scandinavian cardiac outcomes trial (ASCOT)-blood pressure lowering arm (BPLA):: A sub-study on incremental cost-effectiveness of amlodipine-based regimen vs. atenolol-based regimen in primary prevention among hypertensive patients with additional risk factors
Lindgren P; Tang S; Buxton M; Kahan T; Poulter N; Dahlof B; Sever P; Wedel H; Buch J; Jonsson B
Conference publication: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2007;49(9):294A-295A
Economic evaluation of intensive atorvastatin compared to standard simvastatin in patients with acute coronary syndrome from the IDEAL trial
Lindgren P; Jonsson B
Review: EUROPEAN HEART JOURNAL. 2007;28(1):88-136
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary - The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Ryden L; Standl E; Bartnik M; Van den Berghe G; Betteridge J; de Boer M-J; Cosentino F; Jonsson B; Laakso M; Malmberg K; Priori S; Ostergren J; Tuomilehto J; Thrainsdottir I; Vanhorebeek I; Stramba-Badiale M; Lindgren P; Priori SG; Blanc J-J; Budaj A; Camm J; Dean V; Deckers J; Dickstein K; Lekakis J; McGregor K; Metra M; Morais J; Osterspey A; Tamargo J; Zamorano JL; Deckers JW; Bertrand M; Charbonnel B; Erdmann E; Ferrannini E; Flyvbjerg A; Gohlke H; Juanatey JRG; Graham I; Monteiro PF; Parhofer K; Pyorala K; Raz I; Schernthaner G; Volpe M; Wood D
Meeting abstract: VALUE IN HEALTH. 2006;9(6):A353
Cost-utility analysis of eprosartan compared to enalapril and ramipril in the treatment of moderate to severe hypertension in Sweden
Lindgren P; Schwander B; Zollner Y; Jonsson B
Meeting abstract: VALUE IN HEALTH. 2006;9(6):A346-A347
Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation:: European model results based on clarity and commit
Berg J; Lindgren P; Jonsson B
Meeting abstract: VALUE IN HEALTH. 2006;9(6):A333
Economic evaluation of a new airway inflammation monitor in the diagnosis and management of asthma in Germany
Berg J; Lindgren P; Joensson B
Meeting abstract: VALUE IN HEALTH. 2006;9(6):A330
Utility loss and indirect costs after stroke in Sweden
Lindgren P; Glader EL; Jonsson B
Meeting abstract: VALUE IN HEALTH. 2006;9(6):A231-A232
Cost of inpatient and outpatient care of Swedish patients with diabetes mellitus
Ringborg A; Berwick S; Stalhammar J; Martinell M; Lindgren P
Meeting abstract: VALUE IN HEALTH. 2006;9(6):A231
Cost of a major hypoglycaemic event in type 1 and type 2 diabetic patients - A systematic literature review
Lilja U; Asmussen M; Lindgren P
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2006;12:S120-S121
The costs and quality of life of multiple sclerosis in Europe
Kobelt G; Berg J; Lindgren P; Fredrikson S; Jonsson B
Conference publication: EUROPEAN HEART JOURNAL. 2006;27:673
Determinants of cholesterol goal attainment at 12 months in patients not at goal after 3 months treatment with lipid lowering drugs
Lindgren P; Borgstrom F; Stalhammar J; Alemao E; Jonsson L
Conference publication: EUROPEAN HEART JOURNAL. 2006;27:579
The cost of atrial fibrillation management in Europe: a cross-sectional study on resource use during admissions and outpatient clinic visits in the Euro Heart Survey cohort
Nieuwlaat R; Ringborg A; Lindgren P; Le Heuzey JY; Jonsson B; Gabriel S; Crijns HJ
Conference publication: EUROPEAN HEART JOURNAL. 2006;27:378
Lifetime cost-effectiveness of atorvastatin 80 mg compared to generic simvastatin 20-40 mg in secondary prevention based on the IDEAL trial
Lindgren P; Jonsson B
Conference publication: EUROPEAN HEART JOURNAL. 2006;27:773
PCI reduces utility loss after myocardial infarctions in Sweden
Lindgren P; Stenestrand U; Hambraeus K; Wallentin L; Jonsson B
Meeting abstract: ATHEROSCLEROSIS SUPPLEMENTS. 2006;7(3):178
Trial based economic evaluation of intensive atorvastatin compared to standard simvastatin in the ideal trial
Lindgren P; Jonsson B
Conference publication: CIRCULATION. 2006;113(21):E819
Trial based economic evaluation of intensive atorvastatin compared to standard simvastatin in the ideal trial
Lindgren P; Jonsson B
Meeting abstract: VALUE IN HEALTH. 2005;8(6):A134
The cost of multiple sclerosis (MS) in Europe
Berg J; Kobelt G; Lindgren P; Fredrikson S; Jönsson B
Conference publication: CIRCULATION. 2005;112(17):U883
Atorvastatin therapy is cost-effective in individuals with treated hypertension, normal/mildly elevated cholesterol and ≥2 additional risk factors (ASCOT-LLA)
Schwartz JS; Lindgren P; Jonsson B; Mackell JA
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2005;11:S34
Cost of multiple sclerosis in Sweden:: changes in the last decade
Kobelt G; Berg J; Lindgren P; Fredrikson S; Jönsson B
Conference publication: EUROPEAN JOURNAL OF NEUROLOGY. 2005;12:8
European Brain Council:: Epidemiology of brain diseases in Europe
Dodel R; Andlin-Sobocki P; Beghi E; Berg J; Jonsson L; Ekman M; Forsgren L; Jonsson B; Kobelt G; Lindgren P; Olesen J; Westphal M; Wittchen HU
Conference publication: EUROPEAN HEART JOURNAL. 2005;26:367
The cost-effectiveness of clopidogrel based on three trials
Lindgren P; Ringborg A; Jonsson B
Meeting abstract: VALUE IN HEALTH. 2005;8(3):253
9301 cost-effectiveness of long-term therapy with clopidogrel following percutaneous coronary intervention:: A Swedish analysis of the CREDO-trial
Ringborg A; Lindgren P; Jönsson B
Doctoral thesis: 2005
Modeling the economics of prevention
Lindgren P
Meeting abstract: VALUE IN HEALTH. 2004;7(6):694
Cost-effectiveness of reduction in cardiovascular outcomes with atorvastatin in patients with normal to mildly elevated cholesterol levels, treated for hypertension:: The ASCOT-LLA study
Lindgren P; Buxton MJ; Kahan T; Poulter N; Dahlöf B; Sever P; Wedel H; Jönsson B
Meeting abstract: VALUE IN HEALTH. 2004;7(6):688
The cost-effectiveness of clopidogrel in patients undergoing percutaneous coronary intervention in Sweden:: An analysis of PCI-cure
Lindgren P; Stenestrand U; Malmberg K; Jönsson B
Review: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2004;5 Suppl 1:S63-S66
Economic evidence in Parkinson's disease: a review.
Lindgren P
Meeting abstract: VALUE IN HEALTH. 2003;6(6):621
Short and long term cost-effectiveness analysis of clopidogrel in patients with acute coronary syndrome without ST segment elevation (ACS) in Scandinavian countries
Lindgren P; Jönsson B; Spiesser J; Carita P; Gabriel S
Conference publication: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2003;41(6):540A
Modeling the cost-effectiveness of clopidogrel in acute coronary syndromes without ST-segment elevation in Sweden
Lindgren P; Jonsson B
Conference publication: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2003;41(6):383A
Incremental cost-effectiveness of early and long-term clopidogrel in patients undergoing percutaneous coronary infarction in the CURE trial: The PCI-CURE economic analysis
Mehta SR; Weintraub WS; Jonsson B; Lamy A; Mahoney E; Lindgren P; Rather M; Bertrand ME; Zhao F; Chrolavicius S; Fox KA; Yusuf S
Meeting abstract: EUROPEAN HEART JOURNAL. 2003;24:586
Cost-effectiveness analysis of clopidogrel in acute coronary syndromes without ST-segment elevation: a five European countries analysis
Annemans L; Lindgren P; Frei A; Gabriel S; Carita P
Meeting abstract: EUROPEAN HEART JOURNAL. 2003;24:245
Cost-effectiveness analysis of clopidogrel in patients with unstable coronary artery disease undergoing percutaneous coronary interventions: a five European countries analysis
Annemans L; Lindgren P; Frei A; Gabriel S; Spiesser J
Conference publication: CIRCULATION. 2002;106(19):758
The cost-effectiveness of the use of Clopidogrel in acute coronary syndromes based upon the CURE study
Lamy A; Chrolavicius S; Gafni A; Yusuf S; Zhao F; Jönsson B; Lindgren P; Bakhai A; Flather M; Fox KAA; Culler S; Mahoney EM; Weintraub WS
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2001;44(9):S312
Economic consequences of the progression of rheumatoid arthritis in Sweden and the United Kingdom.
Kobelt G; Jonsson L; Lindgren P; Eberhardt K; Young A
Show more

Grants

Who reaps the value of medical innovation? The case of hepatitis C in Sweden
Bank of Sweden Tercentenary Foundation
31 October 2016 - 30 December 2018

Employments

Adjunct Professor, Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, 2021-2029

Degrees and Education

Docent, Karolinska Institutet, 2014
Doctor Of Philosophy, Institute of Environmental Medicine, Karolinska Institutet, 2005

Supervision

Supervision to doctoral degree
- George Keel, Counting what counts: Time-driven activity-based costing in health care, https://openarchive.ki.se/articles/thesis/Counting_what_counts_time-driven_activity-based_costing_in_health_care/26912272?file=48956269, 2020

Articles

All other publications

Grants

Employments

Degrees and Education

Supervision

Supervision to doctoral degree

News from KI

Events from KI